StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –

Elite Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Elite Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $141.01M, up 33.7% year over year. For fiscal 2026 it was $148.87M, up 77.1% from the year before. Over ten years it grew 28.1% a year on average. The highest annual figure on record is $148.87M in fiscal 2026.

Annual revenue

PeriodPeriod endValueChange
FY2026Mar 31, 2026$148.87M+77.1%
FY2025Mar 31, 2025$84.04M+48.4%
FY2024Mar 31, 2024$56.63M+65.8%
FY2023Mar 31, 2023$34.16M+5.9%
FY2022Mar 31, 2022$32.26M+27.1%
FY2021Mar 31, 2021$25.38M+41.0%
FY2020Mar 31, 2020$17.99M+137.8%
FY2019Mar 31, 2019$7.57M+1.5%
FY2018Mar 31, 2018$7.46M-22.6%
FY2017Mar 31, 2017$9.64M-22.9%
FY2016Mar 31, 2016$12.50M+149.2%
FY2015Mar 31, 2015$5.02M+9.0%
FY2014Mar 31, 2014$4.60M+35.2%
FY2013Mar 31, 2013$3.40M+40.4%
FY2012Mar 31, 2012$2.42M-43.2%
FY2011Mar 31, 2011$4.27M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$32.36M-19.5%
Q4 FY2026CQ1 2026Mar 31, 2026$40.75M+27.4%
Q3 FY2026CQ4 2025Dec 31, 2025$31.59M+119.9%
Q2 FY2026CQ3 2025Sep 30, 2025$36.32M+92.4%
Q1 FY2026CQ2 2025Jun 30, 2025$40.21M+113.9%
Q4 FY2025CQ1 2025Mar 31, 2025$32.00M+78.3%
Q3 FY2025CQ4 2024Dec 31, 2024$14.36M-7.6%
Q2 FY2025CQ3 2024Sep 30, 2024$18.88M+33.4%
Q1 FY2025CQ2 2024Jun 30, 2024$18.80M+109.4%
Q4 FY2024CQ1 2024Mar 31, 2024$17.95M+107.7%
Q3 FY2024CQ4 2023Dec 31, 2023$15.54M+68.0%
Q2 FY2024CQ3 2023Sep 30, 2023$14.16M+64.9%
Q1 FY2024CQ2 2023Jun 30, 2023$8.98M+17.0%
Q4 FY2023CQ1 2023Mar 31, 2023$8.64M+12.6%
Q3 FY2023CQ4 2022Dec 31, 2022$9.25M+3.1%
Q2 FY2023CQ3 2022Sep 30, 2022$8.59M+0.3%
Q1 FY2023CQ2 2022Jun 30, 2022$7.67M+8.7%
Q4 FY2022CQ1 2022Mar 31, 2022$7.67M+74.5%
Q3 FY2022CQ4 2021Dec 31, 2021$8.97M+48.4%
Q2 FY2022CQ3 2021Sep 30, 2021$8.56M+15.7%
Q1 FY2022CQ2 2021Jun 30, 2021$7.06M-6.4%
Q4 FY2021CQ1 2021Mar 31, 2021$4.40M-11.1%
Q3 FY2021CQ4 2020Dec 31, 2020$6.05M+19.6%
Q2 FY2021CQ3 2020Sep 30, 2020$7.40M+59.7%
Q1 FY2021CQ2 2020Jun 30, 2020$7.54M+124.4%
Q4 FY2020CQ1 2020Mar 31, 2020$4.95M+268.0%
Q3 FY2020CQ4 2019Dec 31, 2019$5.06M+87.6%
Q2 FY2020CQ3 2019Sep 30, 2019$4.63M+240.0%
Q1 FY2020CQ2 2019Jun 30, 2019$3.36M+55.0%
Q4 FY2019CQ1 2019Mar 31, 2019$1.34M-15.9%
Q3 FY2019CQ4 2018Dec 31, 2018$2.69M+6.3%
Q2 FY2019CQ3 2018Sep 30, 2018$1.36M-16.0%
Q1 FY2019CQ2 2018Jun 30, 2018$2.17M+27.3%
Q4 FY2018CQ1 2018Mar 31, 2018$1.60M+18.3%
Q3 FY2018CQ4 2017Dec 31, 2017$2.54M+8.8%
Q2 FY2018CQ3 2017Sep 30, 2017$1.62M-39.6%
Q1 FY2018CQ2 2017Jun 30, 2017$1.70M–
Q4 FY2017CQ1 2017Mar 31, 2017$1.35M–
Q3 FY2017CQ4 2016Dec 31, 2016$2.33M–
Q2 FY2017CQ3 2016Sep 30, 2016$2.69M–

More Elite Pharmaceuticals figures

See a number that looks wrong?